PKO Investment Management Joint Stock Co Purchases 900 Shares of Regeneron Pharmaceuticals, Inc. $REGN

PKO Investment Management Joint Stock Co boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 5,750 shares of the biopharmaceutical company’s stock after acquiring an additional 900 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Regeneron Pharmaceuticals were worth $4,443,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of REGN. Norges Bank acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the period. Dodge & Cox increased its stake in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after purchasing an additional 724,562 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Regeneron Pharmaceuticals by 8,620.0% during the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Sanford C. Bernstein dropped their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Piper Sandler cut their price target on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Royal Bank Of Canada reduced their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Finally, TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Stock Up 0.4%

NASDAQ REGN opened at $612.50 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a 50-day simple moving average of $673.70 and a 200 day simple moving average of $731.25. Regeneron Pharmaceuticals, Inc. has a twelve month low of $507.61 and a twelve month high of $821.11. The stock has a market cap of $64.75 billion, a PE ratio of 14.92, a PEG ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the business earned $8.22 earnings per share. The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.